The National Pharmaceutical Pricing Authority (NPPA) has implemented a large-scale revision of ceiling prices for over 700 scheduled drug formulations based on a Wholesale Price Index increase of 0.64956%, effective 1 April 2026. The notification covers multiple therapeutic categories including antibiotics, antivirals, and chronic disease medicines, requiring strict compliance with pricing, reporting, and approval provisions under the Drugs (Prices Control) Order, 2013.
The National Pharmaceutical Pricing Authority (NPPA) has notified a comprehensive revision of ceiling prices for more than 700 scheduled drug formulations under the Drugs (Prices Control) Order, 2013.
Based on a Wholesale Price Index increase of 0.64956%, the revised prices will come into effect from 1 April 2026 and cover a wide range of medicines across therapeutic areas including antibiotics, antivirals, oncology, and cardiovascular treatments.
This large-scale update significantly impacts the pharmaceutical market and ensures uniform pricing control across essential medicines.
- Applicable to over 700 scheduled formulations across multiple therapeutic categories
- Manufacturers must align all prices with notified ceiling limits
- Downward revision required where MRP exceeds ceiling price
- WPI-based revision permitted where MRP is below ceiling
- Mandatory Form-II submission within 15 days for price changes
- Retailers must display updated pricing information prominently
This notification strengthens nationwide pricing regulation and ensures broad compliance across the pharmaceutical sector.